Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Breast cancer and the NSABP-B32 sentinel node trial

This is a preview of subscription content, log in to check access.


  1. 1)

    Cabanes PA, Salmon RJ, Vilcoq JR,et al: Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. The Breast Carcinoma Collaborative Group of the Institut Curie.Lancet 339:1245–1248, 1992.

  2. 2)

    Fisher B, Redmond C, Fisher ER,et al: Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation.N Engl J Med 312:674–681, 1985.

  3. 3)

    Hayward JI: The Guy’s Hospital trials on breast conservation. In: Harris JR, Hellman S, Silen W, eds. Conservative Management of Breast Cancer: New Surgical and Radiotherapeutic Techniques. Philadelphia, J.B. Lippincott, pp77–90, 1983.

  4. 4)

    Atkins H, Hayward JL, Klugman DJ, Wayte AB: Treatment of early breast cancer: a report after ten years of a clinical trial.Br Med J 2:423–429, 1972.

  5. 5)

    Langlands AO, Prescott RJ, Hamilton T: A clinical trial in the management of operable cancer of the breast.Br J Surg 67:170–174, 1980.

  6. 6)

    Johansen H, Kaae S, Schiodt T: Simple mastectomy with postoperative irradiation versus extended radical mastectomy in breast cancer. A twenty-five-year follow-up of a randomized trial.Ada Oncol 29:709–715, 1990.

  7. 7)

    Orr RK: The impact of prophylactic axillary node dissection on breast cancer survival-a Bayesian meta-analysis.Ann Surg Oncol 6:109–116, 1999.

  8. 8)

    Krag DN, Single RM: Breast cancer survival according to number of nodes removed.Ann Surg Oncol 10:1152–1159, 2003.

  9. 9)

    Bland KI, Scott-Conner CE, Menck H, Winchester DP: Axillary dissection in breast-conserving surgery for stage I and II breast cancer: a National Cancer Data Base study of patterns of omission and implications for survival.J Am Coll Surg 188:586–595; discussion 95-96, 1999.

  10. 10)

    van der Wal B, Butzelaar R, van der Meij S, Boermeester M: Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer.EurJ Surg Oncol 28:481, 2002.

  11. 11)

    Sosa JA, Diener-West M, Gusev Y,et al: Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer.Ann Surg Oncol 5:140–149, 1998.

  12. 12)

    Mathiesen O, Carl J, Bonderup O, Panduro J: Axillary sampling and the risk of erroneous staging of breast cancer. An analysis of 960 consecutive patients.Acta Oncol 29:721–725, 1990.

  13. 13)

    Axelsson CK, Mouridsen HT, Zedeler K: Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG).Eur J Cancer 28A(8– 9):1415–1418, 1992.

  14. 14)

    Le Voyer TE, Sigurdson ER, Hanlon AL,et al: Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of inter-group trial INT-0089.J Clin Oncol 21:2912–2919, 2003.

  15. 15)

    Tepper JE, O’Connell MJ, Niedzwiecki D,et al: Impact of number of nodes retrieved on outcome in patients with rectal cancer.J Clin Oncol 19:157–163, 2001.

  16. 16)

    Chan AD, Essner R, Wanek LA, Morton DL: Judging the therapeutic value of lymph node dissections for melanoma.J Am Coll Surg 191:16–22; discussion-3, 2000.

  17. 17)

    Saphir O, Amromin G: Obscure axillary lymph-node metastasis in carcinoma of the breast.Cancer 1:238–241, 1948.

  18. 18)

    Weaver DL, Krag DN, Ashikaga T, Harlow SP, O’Connell M: Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study.Cancer 88:1099–1107, 2000.

  19. 19)

    Schoenfeld A, Luqmani Y, Sinnett HD, Shousha S, Coombes RC: Keratin 19 mRNA measurement to detect micrometastases in lymph nodes in breast cancer patients.Br J Cancer 74:1639–1642, 1996.

  20. 20)

    Lockett MA, Baron PL, O’Brien PH,et at: Detection of occult breast cancer micrometastases in axillary lymph nodes using a multimarker reverse transcriptase-polymerase chain reaction panel.J Am Coll Surg 187:9–16, 1998.

  21. 21)

    Heller R, Becker J, Wasselle J,et al: Detection of submicroscopic lymph node metastases in patients with melanoma.Arch Surg 126:1455–1459; discussion 9-60, 1991.

  22. 22)

    Hall JC, Platell C, Hall JL: Surgery on trial: an account of clinical trials evaluating operations.Surgery 124:22–27, 1998.

  23. 23)

    Bonenkamp JJ, Hermans J, Sasako M, van De Velde CJ: Quality control of lymph node dissection in the Dutch randomized trial of D1 and D2 lymph node dissection for gastric cancer.Gastric Cancer 1:152–159, 1998.

  24. 24)

    Leong SP, Donegan E, Heffernon W, Dean S, Katz JA: Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma.Ann Surg Oncol 7:361–366, 2000.

  25. 25)

    Albo D, Wayne JD, Hunt KK,et al: Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer.Am J Surg 182:393–398, 2001.

Download references

Author information

Correspondence to David Krag or Seth Harlow or Thomas Julian.

About this article

Cite this article

Krag, D., Harlow, S. & Julian, T. Breast cancer and the NSABP-B32 sentinel node trial. Breast Cancer 11, 221 (2004). https://doi.org/10.1007/BF02984541

Download citation

Key words

  • Breast
  • Cancer
  • Lymph
  • Sentinel nodes